221 related articles for article (PubMed ID: 32582572)
21. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
[TBL] [Abstract][Full Text] [Related]
22. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
[TBL] [Abstract][Full Text] [Related]
23. Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease.
Schultz KR; Bader S; Paquet J; Li W
Blood; 1995 Dec; 86(11):4344-52. PubMed ID: 7492796
[TBL] [Abstract][Full Text] [Related]
24. Minor H antigens: genes and peptides.
Simpson E; Scott D; James E; Lombardi G; Cwynarski K; Dazzi F; Millrain JM; Dyson PJ
Eur J Immunogenet; 2001 Oct; 28(5):505-13. PubMed ID: 11881817
[TBL] [Abstract][Full Text] [Related]
25. Cytomegalovirus-Associated Inhibition of Hematopoiesis Is Preventable by Cytoimmunotherapy With Antiviral CD8 T Cells.
Renzaho A; Podlech J; Kühnapfel B; Blaum F; Reddehase MJ; Lemmermann NAW
Front Cell Infect Microbiol; 2020; 10():138. PubMed ID: 32373544
[TBL] [Abstract][Full Text] [Related]
26. Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.
La Rosa C; Longmate J; Lingaraju CR; Zhou Q; Kaltcheva T; Hardwick N; Aldoss I; Nakamura R; Diamond DJ
Biol Blood Marrow Transplant; 2019 Apr; 25(4):771-784. PubMed ID: 30562587
[TBL] [Abstract][Full Text] [Related]
27. Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation.
Camargo JF; Komanduri KV
Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):233-238. PubMed ID: 28641094
[TBL] [Abstract][Full Text] [Related]
28. Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation.
Arber C; BitMansour A; Sparer TE; Higgins JP; Mocarski ES; Weissman IL; Shizuru JA; Brown JM
Blood; 2003 Jul; 102(2):421-8. PubMed ID: 12663447
[TBL] [Abstract][Full Text] [Related]
29. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation.
Moins-Teisserenc H; Busson M; Scieux C; Bajzik V; Cayuela JM; Clave E; de Latour RP; Agbalika F; Ribaud P; Robin M; Rocha V; Gluckman E; Charron D; Socié G; Toubert A
J Infect Dis; 2008 Sep; 198(6):818-26. PubMed ID: 18666855
[TBL] [Abstract][Full Text] [Related]
30. In vivo impact of cytomegalovirus evasion of CD8 T-cell immunity: facts and thoughts based on murine models.
Lemmermann NA; Böhm V; Holtappels R; Reddehase MJ
Virus Res; 2011 May; 157(2):161-74. PubMed ID: 20933556
[TBL] [Abstract][Full Text] [Related]
31. H60: A Unique Murine Hematopoietic Cell-Restricted Minor Histocompatibility Antigen for Graft-versus-Leukemia Effect.
Choi EY; Choi K; Nam G; Kim W; Chung M
Front Immunol; 2020; 11():1163. PubMed ID: 32587590
[TBL] [Abstract][Full Text] [Related]
32. Control of cytomegalovirus in bone marrow transplantation chimeras lacking the prevailing antigen-presenting molecule in recipient tissues rests primarily on recipient-derived CD8 T cells.
Alterio de Goss M; Holtappels R; Steffens HP; Podlech J; Angele P; Dreher L; Thomas D; Reddehase MJ
J Virol; 1998 Oct; 72(10):7733-44. PubMed ID: 9733809
[TBL] [Abstract][Full Text] [Related]
33. Natural regulation of immunity to minor histocompatibility antigens.
Robertson NJ; Chai JG; Millrain M; Scott D; Hashim F; Manktelow E; Lemonnier F; Simpson E; Dyson J
J Immunol; 2007 Mar; 178(6):3558-65. PubMed ID: 17339452
[TBL] [Abstract][Full Text] [Related]
34. Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation.
Gondo H; Himeji D; Kamezaki K; Numata A; Tanimoto T; Takase K; Aoki K; Henzan H; Nagafuji K; Miyamoto T; Ishikawa F; Shimoda K; Inaba S; Tsukamoto H; Horiuchi T; Nakashima H; Otsuka T; Kato K; Kuroiwa M; Higuchi M; Shibuya T; Kamimura T; Kuzushima K; Tsurumi T; Kanda Y; Harada M
Int J Hematol; 2004 Dec; 80(5):441-8. PubMed ID: 15646657
[TBL] [Abstract][Full Text] [Related]
35. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants.
Lacey SF; Gallez-Hawkins G; Crooks M; Martinez J; Senitzer D; Forman SJ; Spielberger R; Zaia JA; Diamond DJ
Transplantation; 2002 Sep; 74(5):722-32. PubMed ID: 12352893
[TBL] [Abstract][Full Text] [Related]
36. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus.
Hansen SG; Powers CJ; Richards R; Ventura AB; Ford JC; Siess D; Axthelm MK; Nelson JA; Jarvis MA; Picker LJ; Früh K
Science; 2010 Apr; 328(5974):102-6. PubMed ID: 20360110
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease.
Natzke AM; Shaw JL; McKeller MR; Emo KL; Mullen CA
Biol Blood Marrow Transplant; 2007 Jan; 13(1):34-45. PubMed ID: 17222751
[TBL] [Abstract][Full Text] [Related]
38. Direct antigen presentation is the canonical pathway of cytomegalovirus CD8 T-cell priming regulated by balanced immune evasion ensuring a strong antiviral response.
Büttner JK; Becker S; Fink A; Brinkmann MM; Holtappels R; Reddehase MJ; Lemmermann NA
Front Immunol; 2023; 14():1272166. PubMed ID: 38149242
[TBL] [Abstract][Full Text] [Related]
39. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
40. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
Drobyski WR; Majewski D
Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
